$2.410
+0.160 (+6.64%)At close
RADX Comparative Benchmarking
In the context of the broader market, RADX competes directly with industry leaders such as DCGO and EUDA. With a market capitalization of $34.84M, it holds a significant position in the sector. When comparing efficiency, RADX's gross margin of N/A stands against DCGO's 26.85% and EUDA's 43.77%. Such benchmarking helps identify whether Radiopharm Theranostics Ltd is trading at a premium or discount relative to its financial performance.
Radiopharm Theranostics Ltd Financial Performance
The company has a price-to-sales ratio of 1.094 and a price-to-book ratio of 0.344, indicating that the stock may be undervalued relative to its sales and assets. However, the negative P/E ratio and forward P/E of 0 suggest that the company is currently not profitable, which could be a concern for long-term investors.
Financials
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。